USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS

(19)

(11)

EP 1 879 591 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	04.04.2012 Bulletin 2012/14

(45)	Mention of the grant of the patent:
	25.01.2012 Bulletin 2012/04

(21)	Application number: 06724715.5

(22)	Date of filing: 04.05.2006

(51)

International Patent Classification (IPC):

A61K 31/55^(2006.01)
A61P 3/10^(2006.01)
A61K 45/00^(2006.01)

C07D 471/14^(2006.01)
A61P 25/28^(2006.01)

(86)	International application number:
	PCT/EP2006/004186

(87)	International publication number:
	WO 2006/117221 (09.11.2006 Gazette 2006/45)

(54)	USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS VERWENDUNG VON AZAPAULLONEN ZUR VORBEUGUNG UND BEHANDLUNG PANKREATISCHER AUTOIMMUNKRANKHEITEN UTILISATION D'AZAPAULLONES POUR LA PREVENTION ET LE TRAITEMENT DE TROUBLES AUTO-IMMUNES DU PANCREAS

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30)

Priority:

04.05.2005 EP 05009846
22.07.2005 EP 05015986
24.10.2005 EP 05023168
23.01.2006 EP 06001327

(43)	Date of publication of application:
	23.01.2008 Bulletin 2008/04

(73)	Proprietors:
	DeveloGen Aktiengesellschaft 37079 Göttingen (DE) Technische Universität Carolo-Wilhelmina zu Braunschweig 38106 Braunschweig (DE)

(72)	Inventors:
	MUSSMANN, Rainer 4312 Magden (CH) KUNICK, Conrad 21149 Hamburg (DE) STUKENBROCK, Hendrik 48147 Münster (DE) GEESE, Marcus 37073 Göttingen (DE) KEGEL, Simone 37170 Uslar (DE) BURK, Ulrike 37073 Göttingen (DE)

(74)	Representative: Weiss, Wolfgang et al
	Weickmann & Weickmann Patentanwälte Postfach 86 08 20 81635 München 81635 München (DE)

(56)

References cited: :

EP-A- 1 477 490
WO-A-03/011843
WO-A-2005/104836
US-A1- 2005 090 483

WO-A-02/086107
WO-A-2005/086814
US-A1- 2003 181 439

MEIJER L ET AL: "Pharmacological inhibitors of glycogen synthase kinase 3" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 25, no. 9, September 2004 (2004-09), pages 471-480, XP004552644 ISSN: 0165-6147
COHEN P ET AL: "GSK3 inhibitors: Development and therapeutic potential" NATURE REVIEWS DRUG DISCOVERY 2004 UNITED KINGDOM, vol. 3, no. 6, 2004, pages 479-487, XP002357670 ISSN: 1474-1776 cited in the application
LEOST M ET AL: "Paullones are potent inhibitors of glycogen synthase kinase-3.beta. and cyclin-dependent kinase 5/p25" EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 267, no. 19, 2000, pages 5983-5994, XP002384290 ISSN: 0014-2956
OGAWA NORIHIKO ET AL: "Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4" DIABETES, vol. 53, no. 7, July 2004 (2004-07), pages 1700-1705, XP002390322 ISSN: 0012-1797 cited in the application
MARTINEZ A ET AL: "GLYCOGEN SYNTHASE KINASE 3 (GSK-3) INHIBITORS AS NEW PROMISING DRUGS FOR DIABETES, NEURODEGENERATION, CANCER, AND INFLAMMATION", MEDICINAL RESEARCH REVIEWS, NEW YORK, NY, US, vol. 22, no. 4, 1 January 2002 (2002-01-01), pages 373-384, XP009058328, ISSN: 0198-6325, DOI: DOI:10.1002/MED.10011

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).